Consulting services provided to the Company through Northbrook Consulting, LLC before Ms. Riley's appointment as Chief Strategy Officer; relationship ended December 31, 2024.
| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
Garry Neil
Also a director
Chief Executive Officer
|
72 | Not stated | Not stated | $3,807,581 | |
|
Christopher Sullivan
Chief Financial Officer
|
42 |
Since 2022
4 years
|
2018 | Not reported | |
|
Taylor Boyd
Chief Business Officer
|
37 |
Since 2025
1 year
|
2025 | $3,219,751 | |
|
Mittie Doyle
Chief Medical Officer
|
61 |
Since 2024
2 years
|
Not stated | $1,780,557 | |
|
Jennifer Riley
Chief Strategy Officer
|
51 |
Since 2025
1 year
|
Not stated | Not reported | |
|
Paul Varki
Chief Legal Officer
|
53 |
Since 2024
2 years
|
Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 10, 2026 · updated by the 8-K of Jun 23, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
Michael Heffernan
Board chair
|
61 |
2025
1 year
|
Independent | None stated | Biohaven (NYSE: BHVN) | $509,578 | |
|
Garry Neil
CEO
|
72 |
2022
4 years
|
Not independent | None stated | Celldex Therapeutics, Inc. (Nasdaq: CLDX) | Paid as CEO | |
|
Rita Jain
|
63 |
2025
1 year
|
Independent |
Audit
|
Celldex Therapeutics, Inc. (Nasdaq: CLDX) | $177,579 | |
|
Aaron Kantoff
|
40 |
2024
2 years
|
Independent | None stated | None stated | $128,973 | |
|
Gilla Kaplan, Ph.D.
|
78 |
2020
6 years
|
Independent | None stated | Tyra Biosciences, Inc. (Nasdaq: TYRA) | $126,955 | |
|
Kevin Lind
|
50 |
2025
1 year
|
Independent | None stated | None stated | $456,488 | |
|
Samantha Truex
|
55 |
2024
2 years
|
Independent | None stated | None stated | $127,473 | |
|
Ron Philip
Joined Jun 23, 2026
|
- | - | Independent |
Compensation Committee
Science, Development and Commercial Advisory Committee
|
- | - | |
|
Mitchell Chan
Leaving at the meeting
|
Not stated | Not stated | Independent |
Audit
|
None stated | $133,991 | |
|
Jonathan Goldman
Leaving at the meeting
|
Not stated | Not stated | Independent | None stated | None stated | $128,473 |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
Consulting services provided to the Company through Northbrook Consulting, LLC before Ms. Riley's appointment as Chief Strategy Officer; relationship ended December 31, 2024.
Loading...